Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium valproate for albuminuria in type 2 diabetic nephropathy
IRCT20201023049126N1Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of valproic acid in diabetic glomerulosclerosis (3 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoints: Microalbuminuria level and Glomerular filtration rate. Started Feb 2021; status: completed.
02
Drugs
valproic acid
03
Conditions
diabetic glomerulosclerosis
Beyond the preview
Go deeper on IRCT20201023049126N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201023049126N1.